Bristol-Myers Squibb (BMY)
$54.06 0.37 (0.67%)
10:56 EDT BMY Stock Quote Delayed 15 Minutes
Previous Close $54.42
Market Cap 88.35B
PE Ratio 94.83
Volume (Avg. Vol.) 2.25M
Day's Range 53.95 - 54.59
52-Week Range 42.48 - 57.37
Dividend & Yield 1.60 (2.96%)
BMY Stock Predictions, Articles, and Bristol-Myers Squibb News
- From InvestorPlace
- From the Web
Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.
A weak start for stocks in October will create good entry points for growth investors. Here are seven of the best prospects to look at.
There's a lot in the news this week, from talks of an impeachment to a potential trade war resolution. Buy these healthcare stocks to benefit.
Biotech stocks are still out of favor because of macro uncertainties. But beneath that, investors may find companies trading at deep value.
Low P/E stocks often are cheap stocks for a reason. But these 10 stocks to buy have not just reasonable valuations, but strong bull cases.
Roku, Adobe Systems, Beyond Meat and Bristol-Myers Squibb are our top stock trades. Read on to see what the charts say.
These 10 stocks don't quite qualify as "set it and forget it" plays. All have some degree of risk. But the risks seem worth taking for the potential rewards, which include near-term income, longer-term growth, and potential capital appreciation.
Biotech stocks overall are holding up fairly well amid recent market volatility. Look at which four biotech stocks to buy have staying power.
Amgen's purchase of Celgenes blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space and boost Amgen stock.
Trade talks gave a lift to stocks, while Johnson & Johnson will be in focus after the close. Here's what happened in the stock market today.
Netflix, Amgen, Bristol-Myers Squibb, Aurora Cannabis and Foot Locker are our top stock trades for Tuesday. Here's how to trade them.
Celgene news for Thursday about it selling Otezla has CELG stock on the rise as it moves forward with the Bristol-Myers Squibb merger.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Bristol-Myers Squibb stock touched a multi-year low last month. But the BMY stock price is cheap enough now to take on real risks.
Political pressures regarding drug pricing and Bristol-Myers’ disappointing clinical trails have contributed to a disappointing performance for BMY stock. Still, much of this bearishness could be priced in already.
BMY stock may continue to bounce around, but the months-long selloff is now slowing because Bristol-Myers Squibb is still thriving.
From Real Money
The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data
From The Street
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!